High-dose interferon-α2a exerts potent activity against human immunodeficiency virus type I not associated with antitumor activity in subjects with Kaposi's sarcoma

P. H.Jos Frissen, Frank De Wolf, Peter Reiss, Piet J.M. Bakker, Cees H.N. Veenhof, Sven A. Danner, Jaap Goudsmit, Joep M.A. Lange

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Scopus)


Anti-human immunodeficiency virus type 1 (HIV-1) activity was assessed in HIV-1-infected homosexual and bisexual men receiving 18-36 MIU/day of recombinant interferon (IFN)-α2a for Kaposi's sarcoma (KS). The median baseline HIV-1 RNA level was 4.99 log10 copies/mL. Seventeen subjects (68%) showed an RNA decline ≤.5 log10/mL, with a maximum at week 4 (median decline = 1.91, range = 3.64-1.15; P = .0007), after which RNA levels stabilized. Eight subjects (32%) with lower median initial CD4+ T cell counts (60 vs. 350 x 106/L; P = .01) did not show RNA responses. Neither RNA nor KS responses were negatively affected by IFN-α2a dose modifications. Anti-HIV responses of KS responders (n = 15) and nonresponders (n = 10) did not differ. High-dose IFN-α can exert potent anti-HIV activity that is not associated with anti-KS activity.

Original languageEnglish
Pages (from-to)811-814
Number of pages4
JournalJournal of infectious diseases
Issue number3
Publication statusPublished - 1997


  • AMC wi-co
  • AMC wi-eigen

Cite this